• Number of retrieved oocytes
  

• Number of days of gonadotropin stimulation
  
• Number of hMG ampoules
  
• Number of follicles at hCG administration
  
• Quality of oocytes
  
• Quality of embryos
  
• Poor response rate
  
• Oocyte fertilization rate
  
• Ineffective intervention rate
  
• Clinical pregnancy rate
  
• Implantation rate
  
• Biochemical pregnancy rate
  
• Multiple pregnancy rate
  
• Miscarriage rate
  
• Ectopic pregnancy rate
  

Significant doubts remain about which type of GnRH agonists [GnRHa] administration to be used in controlled ovarian stimulation [COS] cycles. The use of a single-dose depot long-acting GnRHa instead of a daily low dose preparation would be more comfortable for patients, however, inducing a profound pituitary desensitization, it increases the number of gonadotropin ampoules and the duration of the COS cycle without improving pregnancy rates or other clinical outcomes. Thus, some authors recommend a reduction of both dose and/or duration of GnRHa administration. Halving the dose of depot triptorelin, for instance, has been studied against its full dose administration since 1992 with rather similar clinical outcomes. Half-dose depot leuprolide acetate has also resulted in comparable clinical outcomes with standard daily injections in long GnRHa protocol. Reducing the daily doses of short acting GnRHa has been advocated to demonstrate equivalent results to standard doses. To our knowledge, however, the reduced daily doses have not been evaluated against half dose depot forms in long GnRHa protocols. Thus, we originally compared a half-dose depot triptorelin with reduced daily doses of short-acting buserelin in a long protocol for intracytoplasmic sperm injection and embryo transfer [ICSI/ET] cycles.